vs
Apellis Pharmaceuticals, Inc.（APLS）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$349.1M vs $199.9M），PROCORE TECHNOLOGIES, INC.净利率更高（-10.8% vs -29.5%，领先18.7%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.6% vs -5.9%），PROCORE TECHNOLOGIES, INC.自由现金流更多（$109.2M vs $-14.3M），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（13.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
APLS vs PCOR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $349.1M |
| 净利润 | $-59.0M | $-37.6M |
| 毛利率 | — | 80.1% |
| 营业利润率 | -25.6% | -12.3% |
| 净利率 | -29.5% | -10.8% |
| 营收同比 | -5.9% | 15.6% |
| 净利润同比 | -62.2% | 39.6% |
| 每股收益（稀释后） | $-0.40 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $349.1M | ||
| Q3 25 | $458.6M | $338.9M | ||
| Q2 25 | $178.5M | $323.9M | ||
| Q1 25 | $166.8M | $310.6M | ||
| Q4 24 | $212.5M | $302.0M | ||
| Q3 24 | $196.8M | $295.9M | ||
| Q2 24 | $199.7M | $284.3M | ||
| Q1 24 | $172.3M | $269.4M |
| Q4 25 | $-59.0M | $-37.6M | ||
| Q3 25 | $215.7M | $-9.1M | ||
| Q2 25 | $-42.2M | $-21.1M | ||
| Q1 25 | $-92.2M | $-33.0M | ||
| Q4 24 | $-36.4M | $-62.3M | ||
| Q3 24 | $-57.4M | $-26.4M | ||
| Q2 24 | $-37.7M | $-6.3M | ||
| Q1 24 | $-66.4M | $-11.0M |
| Q4 25 | — | 80.1% | ||
| Q3 25 | — | 79.7% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 79.1% | ||
| Q4 24 | — | 81.2% | ||
| Q3 24 | — | 81.4% | ||
| Q2 24 | — | 83.1% | ||
| Q1 24 | — | 83.0% |
| Q4 25 | -25.6% | -12.3% | ||
| Q3 25 | 48.7% | -4.4% | ||
| Q2 25 | -18.6% | -9.3% | ||
| Q1 25 | -50.0% | -11.7% | ||
| Q4 24 | -12.3% | -21.9% | ||
| Q3 24 | -24.0% | -12.3% | ||
| Q2 24 | -14.7% | -5.2% | ||
| Q1 24 | -36.0% | -7.0% |
| Q4 25 | -29.5% | -10.8% | ||
| Q3 25 | 47.0% | -2.7% | ||
| Q2 25 | -23.6% | -6.5% | ||
| Q1 25 | -55.3% | -10.6% | ||
| Q4 24 | -17.1% | -20.6% | ||
| Q3 24 | -29.2% | -8.9% | ||
| Q2 24 | -18.9% | -2.2% | ||
| Q1 24 | -38.5% | -4.1% |
| Q4 25 | $-0.40 | $-0.25 | ||
| Q3 25 | $1.67 | $-0.06 | ||
| Q2 25 | $-0.33 | $-0.14 | ||
| Q1 25 | $-0.74 | $-0.22 | ||
| Q4 24 | $-0.30 | $-0.42 | ||
| Q3 24 | $-0.46 | $-0.18 | ||
| Q2 24 | $-0.30 | $-0.04 | ||
| Q1 24 | $-0.54 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $768.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $768.5M | ||
| Q3 25 | $479.2M | $684.0M | ||
| Q2 25 | $370.0M | $620.9M | ||
| Q1 25 | $358.4M | $566.7M | ||
| Q4 24 | $411.3M | $775.4M | ||
| Q3 24 | $396.9M | $756.9M | ||
| Q2 24 | $360.1M | $735.4M | ||
| Q1 24 | $325.9M | $744.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $1.3B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.3B | ||
| Q3 24 | $237.1M | $1.3B | ||
| Q2 24 | $264.3M | $1.3B | ||
| Q1 24 | $266.7M | $1.2B |
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $2.1B | ||
| Q3 24 | $901.9M | $2.0B | ||
| Q2 24 | $904.5M | $2.0B | ||
| Q1 24 | $831.9M | $1.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $114.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $109.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 31.3% |
| 资本支出强度资本支出/营收 | 0.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $282.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $114.9M | ||
| Q3 25 | $108.5M | $88.5M | ||
| Q2 25 | $4.4M | $30.8M | ||
| Q1 25 | $-53.4M | $66.0M | ||
| Q4 24 | $19.4M | $29.1M | ||
| Q3 24 | $34.1M | $39.3M | ||
| Q2 24 | $-8.3M | $58.7M | ||
| Q1 24 | $-133.0M | $69.1M |
| Q4 25 | $-14.3M | $109.2M | ||
| Q3 25 | $108.3M | $83.1M | ||
| Q2 25 | $4.4M | $27.9M | ||
| Q1 25 | $-53.4M | $62.0M | ||
| Q4 24 | $19.3M | $17.4M | ||
| Q3 24 | — | $35.7M | ||
| Q2 24 | $-8.4M | $56.8M | ||
| Q1 24 | $-133.3M | $67.1M |
| Q4 25 | -7.1% | 31.3% | ||
| Q3 25 | 23.6% | 24.5% | ||
| Q2 25 | 2.5% | 8.6% | ||
| Q1 25 | -32.0% | 20.0% | ||
| Q4 24 | 9.1% | 5.8% | ||
| Q3 24 | — | 12.1% | ||
| Q2 24 | -4.2% | 20.0% | ||
| Q1 24 | -77.3% | 24.9% |
| Q4 25 | 0.1% | 1.6% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | 0.0% | 3.9% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
